Cost-utility of enoxaparin compared with unfractioned heparin in unstable coronary artery disease

BMC Cardiovascular Disorders

Volumn 1, Issue , 2001, Pages

  Nicholson, Tricia ^a   McGuire, Alistair ^b   Milne, Ruairidh ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Economics Department   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; COST BENEFIT ANALYSIS; COST CONTROL; COST UTILITY ANALYSIS; HEART INFARCTION; HUMAN; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNSTABLE ANGINA PECTORIS; ECONOMICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANGINA, UNSTABLE; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; ENOXAPARIN; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS;

EID: 0642281279     PISSN: 14712261     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2261-1-2     Document Type: Article

References (23)

1. Purcell H: The epidemiology of unstable angina. Br J Cardiol 1998, 5:S3-S4
2. Cairns JA, Singer J, Gent M, Holder DA, Rogers D, Sackett DL, et al: One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol 1989, 5:239-246
3. O'Brien TX, Ross J Jr: Non-Q-wave myocardial infarction: incidence, pathophysiology, and clinical course compared with Q-wave infarction. Clin Cardiol 1989, 12:III-3-III-9
4. Detournay B, Huet X, Fagnani F, Montalescot G: Economic evaluation of enoxaparin sodium versus heparin in unstable angina: A French sub-study of the ESSENCE trial. PharmacoEconomics 2000, 18:83-89
5. Cohen M, Turpie AGG: Management of unstable angina and myocardial infarction. Lancet 2000, 356:1194
6. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-QAdditional Wave Coronary Events Study Group. N Engl J Med 1997, 337:447-452
7. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink PJLM, Salein D, et al: Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999, 100:1593-1601
8. Antman EM, Cohen M, Radley D, McCabe CH, Rush J, Premmereur J, et al: Assessment of the treatment effect of Enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B - ESSENCE meta-analysis. Circulation 1999, 100:1602-1608
9. Fox K: The role of the antithrombins in improving outcome in unstable angina. Br J Cardiol 1998, 5:S7-S9
10. Kuch M, Chmielewski M, Swiatowie A, Mamcarz A, Braksator W, Dhizniewski M, et al: Could heparin or enoxaparin added to aspirin alone therapy reduce cardiac events in patients suffering from unstable angina pectoris? - Study performed in 201 patients. Kardiologia Polska 1997, 47:1-140
11. Fox KA, Bosanquet N: Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998, 5:92-105
12. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AG, et al: Economic assessment of low-molecularweight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998, 97:1702-1707
13. Balen RM, Marra CA, Zed PJ, Cohen M, Frighetto L: Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: A Canadian hospital perspective. PharmacoEconomics 1999, 16:533-542
14. O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S: Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000, 139:423-429
15. Nicholson T, Milne R, Stein K: Dalteparin and enoxaparin for unstable angina and non-Q-wave myocardial infarction: update. Development and Evaluation Committee Report No. 108. 2000. Southampton, Wessex Institute for Health Research and Development. [http://www.hta.nhsweb.nhs.uk/rapidhta/]
16. Drummond M, Torrance G, Mason J: Cost-effectiveness league tables: More harm than good? Sci Med 1993, 37:33-40
17. Gerard K, Mooney G: QALY league tables: handle with care. Health Econ 1993, 2:59-64
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996, 17:1-12
19. Rawles J, Light J, Watt M: Quality of life in the first 100 days after suspected acute myocardial infarction - a suitable trial endpoint? J Epidemiol Community Health 1992, 46:612-616
20. Rosser R, Kind P: A scale of valuations of states of illness: is there a social consensus? Int J Epidemiol 1978, 7:347-358
21. Brazier J, Deverill M, Green C, Harper R, Booth A: A review of the use of health status measures in economic evaluation. Health Technol Assess 1999, 3:
22. Gudex C, Kind P, van Dalen H, Durand M-A, Morris J, Williams A: Comparing scaling methods for health state valuations: Rosser revisited. 107. 1993. York, Centre for Health Economics, University of York
23. Purchasing power parities for GDP. 2001 Web 2001 [http://www.oecd.org/std/pppoecd.xls]